SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eiko Lifesciences Ltd (540204)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540204 NSE: Chemicals | Small Cap | Eiko Lifesciences Share Price

₹50.14 0.22 (0.44%)

As on 05-Jun'26 16:59

Eiko Lifesciences Ltd (540204)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540204 NSE: Chemicals | Small Cap | Eiko Lifesciences Share Price

₹50.14 0.22 (0.44%)

As on 05-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹72 Cr.
Current Price
₹50.1
52-Week Low / High
₹46 / 66
TTM EPS
₹2.5
TTM Sales
₹42.1 Cr.
Book Value per Share
₹44.2
P/E Ratio
20.08
Lower than its 5-year historical median
Industry PE
50.2
Price to Book (P/B)
1.13
Lower than its 5-year historical median
Price to Sales (P/S)
1.71
Lower than its 5-year historical median
EV/EBITDA
10.99
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
3.25%
Underperforms industry median
Return on Capital Employed (ROCE)
4.50%
Underperforms industry median
Return on Assets (ROA)
3.08%
Operating Profit Margin
5.3%
Net Profit Margin
5.36%
Gross Profit Margin
8%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
16.33%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
6.17%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
132%
Asset Quality
Promoter Holding
39.91%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹49 Cr.
Equity
₹14.4 Cr.
Face Value
₹10
All Time Low / High
₹6.64 / 95.33

Eiko Lifesciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Eiko Lifesciences Ltd a good quality company?
Eiko Lifesciences Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Eiko Lifesciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Eiko Lifesciences Ltd vs industry peers?
Eiko Lifesciences Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 7.53%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Eiko Lifesciences Ltd?
Promoters hold 39.91% of the Eiko Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Eiko Lifesciences Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -8.36% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Eiko Lifesciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 3.5%6.8%5.6%2.3%3.5%9.2%6%3.8%2.8%4.5%-
Value Creation
Index
-0.8-0.5-0.6-0.8-0.8-0.3-0.6-0.7-0.8-0.7-

Growth Parameters

Sales 0.60.40.50.401225.418.327.932.542
Sales YoY Gr.--28.6%22.5%-26.5%-100%NA111.9%-27.9%52.5%16.3%-
Adj EPS 0.20.50.40.20.21.30.70.70.61.12.5
YoY Gr.-113%-16.3%-61%31.3%523.8%-44.3%-2.7%-22.5%94.6%-
BVPS (₹) 99.312.612.312.41429.830.739.44144.2
Adj Net
Profit
0.10.20.20.10.10.60.70.70.81.54
Cash Flow from Ops. 0.20.20.2-0.20.8-0.8-7.74.2-7.12.1-
Debt/CF from Ops. 1.32.21.5-1.60.3-2.2-0.6000.9-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 57%NA8.5%16.3%
Adj EPS 18.6%38.5%13.6%94.6%
BVPS18.4%26.9%11.2%4.1%
Share Price - -5% -5.8% 1.9%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
2.65.44.21.31.76.43.42.31.92.85.9
Op. Profit
Mgn %
16.964.862.84704.45.25.25.85.37.9
Net Profit
Mgn %
14.34337.119.804.82.83.72.74.68.5
Debt to
Equity
0.10.10.10.10.10.30.20000
Working Cap
Days
9945047582,2390258232365250277115
Cash Conv.
Cycle
310-1410237415314515889

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales0.560.400.490.36011.9925.4118.3227.9332.49
Operating Expenses + 0.460.140.180.190.1711.4724.1017.3626.3130.78
Manufacturing Costs000000.470.840.540.210.93
Material Costs0000010.6122.5816.0925.4129.21
Employee Cost 0.100.060.070.020.070.120.230.230.160.28
Other Costs 0.360.080.110.170.100.270.450.500.530.36
Operating Profit 0.090.260.310.17-0.170.521.310.961.621.72
Operating Profit Margin (%) 16.9%64.8%62.8%47.0%-4.4%5.1%5.2%5.8%5.3%
Other Income + 0.0200.020.020.430.460.670.850.181.02
Exceptional Items 0000000000.34
Interest 00.020.050.030.070.090.480.160.150.13
Depreciation 00.020.060.060.060.060.560.630.660.63
Profit Before Tax 0.110.220.220.100.130.830.941.030.982.32
Tax 0.030.050.040.0300.220.240.260.230.58
Profit After Tax 0.080.170.180.070.130.610.710.770.751.74
PAT Margin (%) 14.3%43.0%37.1%19.8%-5.1%2.8%4.2%2.7%5.4%
Adjusted EPS (₹)0.20.50.40.20.31.40.70.80.61.3
Dividend Payout Ratio (%)0%44.50%0%0%0%0%0%0%0%0%

Valuation of Eiko Lifesciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 3.123.235.555.435.486.1928.6329.4250.6856.42
Share Capital 3.023.023.823.823.823.828.328.3212.8713.76
Reserves 0.100.211.731.611.662.3720.3121.1137.8142.66
Debt +0.250.370.310.260.201.764.55001.75
Long Term Debt00.370.310.260.200.130.05001
Short Term Debt0.2500001.634.50000.76
Minority Interest0000000000
Trade Payables000001.901.351.051.381.11
Others Liabilities 0.020.170.120.070.036.750.360.580.681.09
Total Liabilities 3.393.765.985.765.7116.5934.8931.0452.7460.37

Fixed Assets

Net Fixed Assets +00.490.430.370.310.2514.2913.8813.5714.26
Gross Block00.520.520.520.520.5215.1215.3415.6916.99
Accumulated Depreciation00.020.080.140.210.270.831.462.132.73
CWIP 0000000000
Investments 2.592.453.582.130.500.220.200.054.027.07
Inventories000000.065.460.913.394.02
Trade Receivables0000.0803.414.567.1113.1310.14
Cash Equivalents 0.510.010.730.030.024.070.220.6113.3511.51
Others Assets 0.280.811.243.154.888.5710.178.485.2913.38
Total Assets 3.393.765.985.765.7116.5934.8931.0452.7460.37

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 0.190.190.24-0.190.77-0.83-7.734.22-7.082.05
PBT 0.110.220.220.100.130.830.941.030.982.32
Adjustment 00.040.110.070.06-0.210.380.020.62-0.51
Changes in Working Capital 0.1-0.01-0.05-0.330.6-1.27-8.843.1-8.650.53
Tax Paid -0.02-0.06-0.04-0.03-0.01-0.18-0.210.08-0.03-0.29
Cash Flow From Investing Activity + 0.05-0.38-1.33-0.43-0.65-2.940.590.87-0.55-9.85
Capex 0-0.520000-0.15-0.22-0.35-1.33
Net Investments -2.330.18-0.51-0.101.580.40-00.37-0.38-9.43
Others 2.38-0.05-0.82-0.33-2.23-3.340.750.730.180.91
Cash Flow From Financing Activity + 0.250.151.82-0.08-0.137.813.28-4.7020.365.97
Net Proceeds from Shares 0020000.95020.504.35
Net Proceeds from Borrowing 00.41-0.05-0.05-0.061.562.79-4.5501.75
Interest Paid 0-0.01-0.05-0.03-0.07-0.09-0.46-0.15-0.14-0.13
Dividend Paid 00-0.090000000
Others 0.25-0.25-0006.34-000-0
Net Cash Flow 0.49-0.040.72-0.71-0.014.05-3.850.4012.73-1.83

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)2.65.354.161.322.3410.534.052.651.883.25
ROCE (%)3.536.835.62.253.469.185.963.772.824.5
Asset Turnover Ratio0.170.110.10.0601.080.990.560.670.57
PAT to CFO Conversion(x)2.381.121.33-2.715.92-1.36-10.895.48-9.441.18
Working Capital Days
Receivable Days00084.80010457.30116.20132.30130.70
Inventory Days000001.9039.7063.4028.1041.60
Payable Days0000032.6026.2027.2017.4015.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Eiko Lifesciences Ltd FAQs

The current trading price of Eiko Lifesciences on 05-Jun-2026 16:59 is ₹50.14.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Eiko Lifesciences stood at ₹71.93 Cr

The latest P/E ratio of Eiko Lifesciences as of 04-Jun-2026 is 20.08.

The latest P/B ratio of Eiko Lifesciences as of 04-Jun-2026 is 1.13.

The 52-week high of Eiko Lifesciences is ₹65.90 and the 52-week low is ₹45.90.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Eiko Lifesciences is ₹42.13 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Eiko Lifesciences Ltd is a below average quality company.

The key valuation ratios of Eiko Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Eiko Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Eiko Lifesciences Ltd

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×